The overall objective of the proposed study is to define an efficacious antifibrotic drug which can be therapeutically used to prevent and/or reverse the interstitial pulmonary fibrosis (IPF) seen in humans. IPF is a crippling and potentially lethal disease which may result from a wide range of processes of known and unknown origins. A variety of compounds has been tested in the past for their antifibrotic potential in the animal model of lung fibrosis, but their therapeutic desirability has been severely limited due to systemic toxicity following long term treatment. The knowledge that the pharmacological intervention for inhibition of collagen synthesis and accumulation can be successfully targeted at the transcriptional level as demonstrated by treatment with interferons (INFs) and their inducers, opens the feasibility of a novel therapeutic approach for the management of IPF. Therefore, the specific aims of the proposed study are: 1) to evaluate the antifibrotic potential of alpha, beta and gamma INFs and their inducers in the bleomycin-rodent model of lung fibrosis; 2) to investigate whether or not INF inducers exert their antifibrotic effect by inducing INFs in serum and lung, as documented, either by measuring the INF levels by an in vitro antiviral assay or by measuring the activities of two INF-mediated enzymes (2-5A synthetase and kinase-P67K); 3) to investigate whether or not the antifibrotic effect of INFs and their inducers resides in their ability to suppress the bleomycin-induced increases in mRNAs responsible for the synthesis of Type I and Type III procollagens in the lung; 4) to investigate whether or not the antifibrotic effect of INFs and their inducers is associated with an alteration in the hemoprotein metabolism of lung; and 5) to assess the direct effects of INFs and their inducers on the functionality of cultured lung fibroblasts with respect to growth, collagen synthesis at the gene expression level, secretion and degradation. A multidisciplinary approach, as proposed in this project will not only explore the feasibility of a novel therapeutic approach to lung fibrosis in vivo but it will also unravel the cellular mechanisms important in the pathogenesis of fibrotic processes. If the adverse side effects of INFs and INF-inducers prove to be acceptable, they might be useful in the therapy of fibrotic diseases including IPF.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL027354-10
Application #
3339132
Study Section
Toxicology Subcommittee 2 (TOX)
Project Start
1981-07-01
Project End
1994-06-30
Budget Start
1990-07-01
Budget End
1991-06-30
Support Year
10
Fiscal Year
1990
Total Cost
Indirect Cost
Name
University of California Davis
Department
Type
Schools of Veterinary Medicine
DUNS #
094878337
City
Davis
State
CA
Country
United States
Zip Code
95618
Chen, J; Giris, N (1997) Species differences in PAF receptor binding in the lungs between hamster and guinea pig. J Lipid Mediat Cell Signal 16:63-74
Wild, J S; Hyde, D M; Hubbell, H R et al. (1996) Dose-related effects of Ampligen (poly(I).poly(C12U)), a mismatched double-stranded RNA, in a bleomycin-mouse model of pulmonary fibrosis. Exp Lung Res 22:375-91
Giri, S N; Hollinger, M A (1996) Effect of nordihydroguaiaretic acid and ibuprofen on bleomycin and hyperoxia-induced changes in lung superoxide dismutase, prostaglandins and lethality. Arch Toxicol 70:271-6
Braun, R K; Sterner-Kock, A; Kilshaw, P J et al. (1996) Integrin alpha E beta 7 expression on BAL CD4+, CD8+, and gamma delta T-cells in bleomycin-induced lung fibrosis in mouse. Eur Respir J 9:673-9
Giri, S N; Sharma, A K; Hyde, D M et al. (1995) Amelioration of bleomycin-induced lung fibrosis by treatment with the platelet activating factor receptor antagonist WEB 2086 in hamsters. Exp Lung Res 21:287-307
Giri, S N; Hollinger, M A (1995) Effect of cadmium on lung lysosomal enzymes in vitro. Arch Toxicol 69:341-5
Gurujeyalakshmi, G; Giri, S N (1995) Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression. Exp Lung Res 21:791-808
Iyer, S N; Wild, J S; Schiedt, M J et al. (1995) Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J Lab Clin Med 125:779-85
Blaisdell, R J; Giri, S N (1995) Mechanism of antifibrotic effect of taurine and niacin in the multidose bleomycin-hamster model of lung fibrosis: inhibition of lysyl oxidase and collagenase. J Biochem Toxicol 10:203-10
Blaisdell, R J; Schiedt, M J; Giri, S N (1994) Dietary supplementation with taurine and niacin prevents the increase in lung collagen cross-links in the multidose bleomycin hamster model of pulmonary fibrosis. J Biochem Toxicol 9:79-86

Showing the most recent 10 out of 41 publications